for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Apellis Pharmaceuticals Inc

APLS.OQ

Latest Trade

28.16USD

Change

1.68(+6.34%)

Volume

417,300

Today's Range

26.36

 - 

28.63

52 Week Range

11.45

 - 

33.18

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.48
Open
26.40
Volume
417,300
3M AVG Volume
11.11
Today's High
28.63
Today's Low
26.36
52 Week High
33.18
52 Week Low
11.45
Shares Out (MIL)
63.70
Market Cap (MIL)
1,686.66
Forward P/E
-6.63
Dividend (Yield %)
--

Latest Developments

More

Apellis Pharmaceuticals Says Currently Enrolling Two Global Confirmatory Phase 3 Studies For Patients With GA

Apellis Pharmaceuticals Announces Pricing Of Offering Of Convertible Senior Notes

Apellis Pharmaceuticals Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Industry

Biotechnology & Drugs

Contact Info

6400 Westwind Way Ste a

+1.502.2414114

http://apellis.com/

Executive Leadership

Gerald L. Chan

Independent Chairman of the Board

Cedric Francois

President, Chief Executive Officer, Co-Founder, Director

Pascal Deschatelets

Co-Founder, Chief Operating Officer

Timothy Sullivan

Chief Financial Officer, Treasurer

Thomas Lackner

Senior Vice President, Head of Europe

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.670

2018

-2.340

2019(E)

-3.993
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
10.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.21
LT Debt To Equity (MRQ)
4.21
Return on Investment (TTM)
-72.20
Return on Equity (TTM)
-66.53

Latest News

Latest News

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up